NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, announced today the Company’s support for the Generating Antibiotic Incentives Now (GAIN) Act of 2011 (H.R. 2182). The GAIN Act was reintroduced today by Representative Phil Gingrey, M.D. (R-Ga.), to provide incentives for the development of infectious disease products to address the growing epidemic of antibiotic resistant infections. The bill recommends that qualified infectious disease products receive both Fast Track Designation and Priority Review from the Food and Drug Administration and that these badly-needed antibiotics receive an additional five years of market exclusivity. The bill was co-sponsored by Representatives Diana DeGette (D-Colo.), Gene Green (D-Texas), Anna Eshoo (D-Calif.), Mike Rogers (R-Mich.), Ed Whitfield (R-Ky.) and John Shimkus (R-Ill.).
